{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:51:40Z","timestamp":1784829100935,"version":"3.55.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overall survival (OS) is the gold standard endpoint in oncology trials but requires long follow-up and may be confounded by post-protocol treatments. Radiographic progression-free survival (rPFS) is used as an earlier endpoint in metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the validity of rPFS as a surrogate for OS in first-line, asymptomatic\/mildly symptomatic, androgen receptor pathway inhibitor (ARPi) na\u00efve, mCRPC using methods recommended by Germany\u2019s Institute for Quality and Efficiency in Health Care (IQWiG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A systematic search in Ovid\u00ae identified randomized controlled trials reporting both rPFS and OS. Trial-level rPFS-OS correlations of hazard ratios (HRs) were calculated using bivariate random-effects meta-analysis (BRMA) and weighted linear regression (WLR). Correlation strength was interpreted per IQWiG criteria. The surrogate threshold effect (STE) was estimated to assess surrogacy. Leave-one-out cross-validation (LOOCV) assessed model robustness. The primary analysis included trials meeting the proportional hazards (PH) assumption. Sensitivity analyses included trials violating PH and further excluded outliers outside the 95% confidence intervals (CIs) in the correlation plot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven RCTs were identified. The primary analysis (n\u2009=\u200910 trials) yielded medium correlations (BRMA R2: 0.78 [95% CI: 0.53-0.90]; WLR R2: 0.65 [0.40-0.90]; STE: 0.83). Sensitivity analyses yielded medium (n\u2009=\u200911 trials) and strong (n\u2009=\u20098 trials) correlations. LOOCV showed good predictive accuracy (75%-82%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results suggest rPFS is a valid surrogate for OS in first-line ARPi na\u00efve mCRPC per IQWiG criteria. A statistically significant OS effect can be inferred for a trial demonstrating an upper confidence limit of HR\u2009&amp;lt;\u20090.83 in rPFS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf425","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:31:40Z","timestamp":1767702700000},"source":"Crossref","is-referenced-by-count":1,"title":["Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi na\u00efve metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"given":"Elena","family":"Castro","sequence":"first","affiliation":[{"name":"Hospital Universitario 12 de Octubre Department of Medical Oncology, , Madrid 28041,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Paganelli","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 Value & Evidence, , Burlington, ON, L7N 3H8,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 Value & Evidence, , Burlington, ON, L7N 3H8,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Haltner","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 Data Analytics and Evidence Synthesis, , New York, NY 10018,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Value & Evidence, , New York, NY 10001,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Chang","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Value & Evidence, , New York, NY 10001,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1415-8055","authenticated-orcid":false,"given":"Imtiaz A","family":"Samjoo","sequence":"additional","affiliation":[{"name":"EVERSANA\u2122 Value & Evidence, , Burlington, ON, L7N 3H8,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2026012601220454800_oyaf425-B1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on prostate cancer epidemiology and risk factors\u2014a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"2026012601220454800_oyaf425-B2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026012601220454800_oyaf425-B3","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2003.08.156","article-title":"The costs of conducting clinical research","volume":"21","author":"Emanuel","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026012601220454800_oyaf425-B4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"2026012601220454800_oyaf425-B5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026012601220454800_oyaf425-B6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamaoncol.2017.5808","article-title":"Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial","volume":"4","author":"Rathkopf","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026012601220454800_oyaf425-B7","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1111\/bju.12589","article-title":"Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer","volume":"114","author":"Sonpavde","year":"2014","journal-title":"BJU Int"},{"key":"2026012601220454800_oyaf425-B8","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2008.18.9159","article-title":"Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer","volume":"27","author":"Halabi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026012601220454800_oyaf425-B9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clgc.2021.11.007","article-title":"Correlation between imaging-based intermediate endpoints and overall survival in men with metastatic castration-resistant prostate cancer: analysis of 28 randomized trials using the prostate cancer clinical trials working group (PCWG2) criteria in 16,511 patients","volume":"20","author":"Woo","year":"2022","journal-title":"Clin Genitourin \u00adCancer"},{"key":"2026012601220454800_oyaf425-B10","article-title":"NICE DSU technical support document 20: multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints","author":"Bujkiewicz","year":"2019"},{"key":"2026012601220454800_oyaf425-B11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0272989X21994553","article-title":"Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international health technology assessment agencies","volume":"41","author":"Ciani","year":"2021","journal-title":"Med Decis Making"},{"key":"2026012601220454800_oyaf425-B12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","article-title":"Surrogate endpoints in health technology assessment: an international review of methodological guidelines","volume":"38","author":"Grigore","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2026012601220454800_oyaf425-B13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/pst.2219","article-title":"Informed decision-making: statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments","volume":"21","author":"Weir","year":"2022","journal-title":"Pharm Stat"},{"key":"2026012601220454800_oyaf425-B14","volume-title":"Executive summary of rapid report A10-05: validity of surrogate endpoints in oncology","author":"IQWiG","year":"2011"},{"key":"2026012601220454800_oyaf425-B15","author":"Page","year":"2024"},{"key":"2026012601220454800_oyaf425-B16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026012601220454800_oyaf425-B17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol."},{"key":"2026012601220454800_oyaf425-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2026012601220454800_oyaf425-B19","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026012601220454800_oyaf425-B20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/biostatistics\/kxm023","article-title":"An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown","volume":"9","author":"Riley","year":"2008","journal-title":"Biostatistics"},{"key":"2026012601220454800_oyaf425-B21","first-page":"404","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks JJ, Higgins JPT, Altman DG","year":"2024"},{"key":"2026012601220454800_oyaf425-B22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"key":"2026012601220454800_oyaf425-B23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"2026012601220454800_oyaf425-B24","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s12325-022-02140-2","article-title":"Enzalutamide in chemotherapy-Na\u00efve metastatic castration-resistant prostate cancer: an Asian multiregional, randomized study","volume":"39","author":"Pu","year":"2022","journal-title":"Adv Ther"},{"key":"2026012601220454800_oyaf425-B25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012601220454800_oyaf425-B26","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026012601220454800_oyaf425-B27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026012601220454800_oyaf425-B28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"2026012601220454800_oyaf425-B29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026012601220454800_oyaf425-B30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"2026012601220454800_oyaf425-B31","doi-asserted-by":"crossref","first-page":"S957","DOI":"10.1016\/j.annonc.2023.09.2721","article-title":"1771MO pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): randomized double-blind phase III KEYNOTE-641 study","volume":"34","author":"Graff","year":"2023","journal-title":"Ann Oncol"},{"key":"2026012601220454800_oyaf425-B32","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","article-title":"LBA1 a randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann Oncol"},{"key":"2026012601220454800_oyaf425-B33","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.22.02394","article-title":"Randomized phase III study of enzalutamide compared with enzalutamide plus abiraterone for metastatic castration-resistant prostate cancer (alliance A031201 trial)","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026012601220454800_oyaf425-B34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026012601220454800_oyaf425-B35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jval.2025.01.005","article-title":"A comparison of the performance of six surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis","volume":"28","author":"Vickers","year":"2025","journal-title":"Value Health"},{"key":"2026012601220454800_oyaf425-B36","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00228-019-02736-8","article-title":"Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis","volume":"75","author":"Chen","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2026012601220454800_oyaf425-B37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5057","volume-title":"Radiographic Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Men with Metastatic Castrate-Resistant Prostate Cancer","author":"Halabi","year":"2021"},{"key":"2026012601220454800_oyaf425-B38","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jval.2022.09.134","article-title":"CO55 radiographic Progression-Free survival (RPFS) as a surrogate endpoint for overall survival (OS) in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (MCRPC): a correlation meta-analysis","volume":"25","author":"Leung","year":"2022","journal-title":"Value Health"},{"key":"2026012601220454800_oyaf425-B39","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-06-1885","article-title":"The association between measures of progression and survival in castrate-metastatic prostate cancer","volume":"13","author":"Scher","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026012601220454800_oyaf425-B40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2022.04.027","article-title":"Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: a correlation meta-analysis","volume":"170","author":"Ajani","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026012601220454800_oyaf425-B41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-019-05262-4","article-title":"Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"176","author":"Lux","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026012601220454800_oyaf425-B42","author":"Julian Higgins","year":"2023"},{"key":"2026012601220454800_oyaf425-B43","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026012601220454800_oyaf425-B44","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026012601220454800_oyaf425-B45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026012601220454800_oyaf425-B46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","article-title":"Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial","volume":"87","author":"de Bono","year":"2025","journal-title":"Eur Urol"},{"key":"2026012601220454800_oyaf425-B47","volume-title":"Activation of the AKT Pathway and Outcomes in Patients (Pts) Treated with or without Ipatasertib (Ipat) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Next-Generation Sequencing (NGS) Data from the Phase III IPATential150 Trial","author":"Sweeney","year":"2022"},{"key":"2026012601220454800_oyaf425-B48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"2026012601220454800_oyaf425-B49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA141","volume-title":"Final Overall Survival (OS) with Talazoparib (TALA) + Enzalutamide (ENZA) as First-Line (1L) Treatment in Patients (Pts) with Homologous Recombination Repair (HRR)-Deficient Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the Phase 3 TALAPRO-2 Trial","author":"Fizazi","year":"2025"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf425\/66285464\/oyaf425.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf425\/66285464\/oyaf425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf425\/66285464\/oyaf425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T06:22:13Z","timestamp":1769408533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf425\/8415882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf425","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,6]]},"article-number":"oyaf425"}}